Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers.

@article{Addy2008SafetyTP,
  title={Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers.},
  author={Carol Addy and Susie Li and Nancy Agrawal and Julie M Stone and Anup K Majumdar and Ling Zhong and Hankun Li and Jinyu Yuan and Andrea L. Maes and Paul Rothenberg and Jos{\'e}e C{\^o}t{\'e} and Kim M Rosko and Corinne E. Cummings and Steven Warrington and Malcolm Boyce and Keith Gottesdiener and Aubrey S Stoch and John J. Wagner},
  journal={Journal of clinical pharmacology},
  year={2008},
  volume={48 4},
  pages={418-27}
}
Taranabant is a novel cannabinoid CB-1 receptor (CB1R) inverse agonist in clinical development for the treatment of obesity. This double-blind, randomized, placebo-controlled, single oral dose study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of taranabant (0.5-600 mg) in 24 healthy male volunteers. Single-dose AUC(0-infinity) and C(max) values for taranabant increased approximately linearly with dose up to 200 mg, with slightly less than dose-proportional… CONTINUE READING
21 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

Similar Papers

Loading similar papers…